T-3D959 is under clinical development by T3D Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect T-3D959’s likelihood of approval (LoA) and phase transition for Huntington Disease took place on 30 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their T-3D959 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
T-3D959 (DB959) is under development for the treatment of non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, and Huntington disease. The drug candidate is formulated as a capsules and administered by oral route. DB-959 is a new chemical entity that acts by targeting peroxisome proliferator-activated receptor (PPAR) delta/gamma receptors. It was also under development for the treatment of type 2 diabetes and dyslipidemia.
It was under development for the treatment of Alzheimer’s disease.
T3D Therapeutics overview
T3D Therapeutics is a drug discovery company that develops solutions for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The company’s pipeline product include T3D-959 an optimal disease remedial therapeutic for the treatment of Alzheimer’s disease. It provides a potential to improve dysfunctional glucose and lipid metabolism that is inherent in other neurodegenerative diseases such as certain orphan diseases. The company’s product is an orally-delivered once-a-day medicine for patients with mild to moderate stage of Alzheimer’s disease. T3D Therapeutics is headquartered in Durham, North Carolina, the US.
Quick View T-3D959 LOA Data
|Highest Development Stage|